Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2019 December;61(4) > Panminerva Medica 2019 December;61(4):444-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   Freefree

Panminerva Medica 2019 December;61(4):444-8

DOI: 10.23736/S0031-0808.18.03575-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Temporary kidney dysfunction: supplementation with Meriva® in initial, transient kidney micro-macro albuminuria

Andrea LEDDA 1, 2, Gianni BELCARO 1, 2 , Beatrice FERAGALLI 1, 2, Morio HOSOI 1, 2, Marisa CACCHIO 1, 2, Roberta LUZZI 1, 2, Mark DUGALL 1, 2, Roberto COTELLESE 1, 2

1 Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy; 2 International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy



BACKGROUND: The aim of this registry was to evaluate the efficacy of Meriva® in subjects with temporary kidney dysfunction (TKD) and increased oxidative stress levels. TKD was a casual finding on urinary tests after reported side effects following drug consumption, a clinical event or dehydration.
METHODS: Patients followed either standard management (SM) or SM plus Meriva® (Curcumin Phytosome®) supplementation (3 capsules/day, corresponding to 1.5 g of Meriva® containing 300 mg of curcumin in a bioavailable delivery form). The follow-up period lasted 4 weeks. Subjects were divided according to macroalbuminuria (>300 mg albumin on 24 hours) or microalbuminuria (<300 mg/day albuminuria).
RESULTS: Albuminuria decreased in all subjects, with a statistically significant improvement in the supplement group compared with controls (P<0.05). Oxidative stress level was high in all microalbuminuria subjects at inclusion; it was significantly more reduced in the supplement group (P<0.05) after 4 weeks. During follow-up blood pressure values were controlled; all subjects were under one single antihypertensive. Blood and urinary tests at 4 weeks were normalized in all subjects. Fatigue was significantly decreased or disappeared in most supplemented subjects at 4 weeks, with better results than in controls. Compliance and tolerability to Meriva® were good.
CONCLUSIONS: This registry study indicates that albuminuria - marker of TKD - is safely ameliorated with the standardized supplement Meriva®. Studies are needed to evaluate the effect of Meriva® in subjects with more significant clinical conditions (i.e. diabetics) or risk factors.


KEY WORDS: Curcumin; Oxidative stress; Fatigue; Albuminuria; Kidney

inizio pagina